A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Completed · Phase 2 · Has a placebo group
Conditions studied: Nonalcoholic Steatohepatitis
In brief
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
Key facts
- Study ID
- NCT05809934
- Run by
- AstraZeneca
- People needed
- 220
- Starts
- 2023-03-15
- Expected to finish
- 2025-09-29
- Last updated by the study team
- 2025-10-28
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Santiago, Chile
- Research Site — Valdivia, Chile
- Research Site — Baotou, China
- Research Site — Beijing, China
- Research Site — Beijing, China
- Research Site — Chengdu, China
- Research Site — Fuzhou, China
- Research Site — Guangzhou, China
- Research Site — Hangzhou, China
- Research Site — Liaocheng, China
- Research Site — Nanchang, China
- Research Site — Qingdao, China
- Research Site — Shanghai, China
- Research Site — Shanghai, China
- Research Site — Shanghai, China
- Research Site — Shenyang, China
- Research Site — Taiyuan, China
- Research Site — Wenzhou, China
- Research Site — Xi'an, China
- Research Site — Xuzhou, China
- Research Site — Zhenjiang, China
- Research Site — Cartagena, Colombia
- Research Site — Konstanz, Germany
- Research Site — Magdeburg, Germany
- Research Site — Santiago, Chile
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.